Subtype
Vestibulocochlear Nerve Neoplasm
CI-CAN-00001649Explore in graph →
Non-malignant19 active trials
- NCIt
- C5120
Loading cancer entity…
Subtype
CI-CAN-00001649Explore in graph →
Clinical trials
83 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01199978 | Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma | active not recruiting | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04374305 | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)(INTUITT-NF2) | recruiting | Phase 2 | 109 | Scott R. Plotkin, MD, PhDOTHER | 1 | Sep 2, 2026 |
| clinicaltrials |
| NCT07713745 | Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)(PRIME-NF2) | not yet recruiting | Phase 2 | 200 | Beijing Tiantan HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07707947 | Selumetinib for NF2-Related Schwannomatosis(ASSIST) | not yet recruiting | Phase 2 | 20 | Beijing Tiantan HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07708285 | Luvometinib in Combination With Serplulimab for NF2-Related Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Beijing Tiantan HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06517888 | Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma | recruiting | Phase 1 / Phase 2 | 27 | Akouos, Inc.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT04283669 | Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas(NF110) | completed | Phase 2 | 12 | University of Alabama at BirminghamOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06322342 | Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent | completed | Phase 2 | 18 | Reveal Pharmaceuticals Inc.INDUSTRY | 1 | Dec 26, 2025 | clinicaltrials |
| NCT03079999 | Study of Aspirin in Patients With Vestibular Schwannoma | active not recruiting | Phase 2 | 97 | Massachusetts Eye and Ear InfirmaryOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03095248 | Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors(SEL-TH-1601) | terminated | Phase 2 | 10 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT01345136 | Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma | terminated | Phase 2 | 4 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04801953 | Nimodipine in Vestibular Schwanommas | unknown | Phase 2 | 30 | Medical University of ViennaOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT04351373 | Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560 | completed | Phase 2 | 12 | Mayo ClinicOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02934256 | Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors(Icotinib) | completed | Phase 2 | 10 | Li PengOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT01125046 | Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas | completed | Phase 2 | 50 | Northwestern UniversityOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT01207687 | Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2018 | clinicaltrials |
| NCT03393689 | RGD PET/MRI in Sporadic Vestibular Schwannoma | unknown | Phase 2 | 40 | Rigshospitalet, DenmarkOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT02104323 | Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors(Endostatin) | completed | Phase 2 | 20 | Beijing Tiantan HospitalOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT00973739 | Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors | completed | Phase 2 | 21 | NYU Langone HealthOTHER | 1 | Mar 22, 2016 | clinicaltrials |
Data updated 19 days agoSource updated Sep 11, 2026source: clinicaltrials